Fig. 1: Overall study design and follow-up blood sample collection for cis-eQTM analysis in COVID-19 patients. | Communications Biology

Fig. 1: Overall study design and follow-up blood sample collection for cis-eQTM analysis in COVID-19 patients.

From: Identification of reactive CpGs and RNA expression in early COVID-19 through cis-eQTM analysis reflecting disease severity and recovery

Fig. 1: Overall study design and follow-up blood sample collection for cis-eQTM analysis in COVID-19 patients.

A Overview of blood sampling and analysis design; The marker discovery cohort consisted of hospitalized COVID-19 patients, stratified into Mild-Moderate (MM) (N = 37) and Severe-Critical (SC) (N = 9) groups, and was used to identify severity-associated cis-eQTM markers. The comparison cohort was composed of two independent reference groups: the ‘Convalescent group’ (N = 90) comprising individuals who recovered from COVID-19 and provided a single blood sample 4 to 12 weeks post-infection, and the ‘Healthy Controls’ group (N = 344), consisting of pre-pandemic individuals with no history of SARS-CoV-2 infection. B Clinical follow-up duration of 46 Hospitalized COVID-19 patients. The green and red points indicate MM and SC groups, respectively. Sample C19-C014(*), excluded DEG analysis due to QC failure, was retained in methylation analysis. In panel (A), the DNA, RNA, and blood icons were adapted from Flaticon (https://www.flaticon.com), and the remaining elements were created using icons available in Microsoft PowerPoint.

Back to article page